Missing Links? Citation Matrix | Graphs | Glossary HistCite Guide About |
Nodes: 1975,
Authors: 5409,
Journals: 512,
Outer References: 13295,
Words: 3300
Collection span: 1980 - 2004
View: Overview. Sorted by first author.
Page 1: 1 2 3 4 5 6 7
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
---|---|---|---|---|---|
1 | 4 | 28 | 441 1995 BRAZILIAN JOURNAL OF MEDICAL AND BIOLOGICAL RESEARCH 28(10):1069-1076 AARESTRUP FM; GONCALVESDACOSTA SC; SARNO EN THE EFFECT OF THALIDOMIDE ON BCG-INDUCED GRANULOMAS IN MICE | 2 | 9 |
2 | 12 | 13 | 1788 2003 LEUKEMIA & LYMPHOMA 44(6):989-991 Abdalla SH; Mahmoud S Thalidomide in relapsed or refractory multiple myeloma: How much and for how long? | 1 | 1 |
3 | 0 | 0 | 1640 2003 BLOOD 102(11):453A-454A Abonour R; Ganjoo K; Fausel C; Yiannoutsos C; Juliar BE; Wood LL; Smith GG; Walker P; Cripe LD A phase II study of oral cyclophosphamide, thalidomide, and prednisone (CTP) for patients with relapsed or refractory multiple myeloma, a Hoosier Oncology Group (HOG) trial: HEM01-21. | 0 | 0 |
4 | 12 | 33 | 961 2000 CLINICAL INFECTIOUS DISEASES 30(5):826-831 Aboulafia DM Inflammatory pseudotumor causing small bowel obstruction and mimicking lymphoma in a patient with AIDS: Clinical improvement after initiation of thalidomide treatment | 1 | 4 |
5 | 0 | 6 | 310 1991 JOURNAL OF LIQUID CHROMATOGRAPHY 14(4):667-673 ABOULENEIN HY; ISLAM MR DIRECT HPLC SEPARATION OF THALIDOMIDE ENANTIOMERS USING CELLULOSE TRIS-4-METHYLPHENYL BENZOATE CHIRAL STATIONARY PHASE | 9 | 17 |
6 | 4 | 22 | 1899 2004 EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES 21(4):465-469 Abraham MH Hydrogen bond and other descriptors for thalidomide and its N-alkyl analogs; prediction of physicochemical and biological properties | 0 | 0 |
7 | 2 | 4 | 1484 2002 JOURNAL OF CLINICAL ONCOLOGY 20(4):1147-1149 Abramson N; Stokes PK; Luke M; Marks AR; Harris JM Ovarian and papillary-serous peritoneal carcinoma: Pilot study with thalidomide | 0 | 3 |
8 | 1 | 3 | 1058 2000 TERATOLOGY 62(3):172-173 Adams J; Buttar HS; Chambers C; Collins TFX; Graham JM; Jones KL; Kweder S; Mitala J; Polifka JE; Schwetz BA; Public Affairs Comm Teratology society public affairs committee position paper: Thalidomide | 0 | 1 |
9 | 19 | 38 | 886 2000 ANTI-CANCER DRUGS 11(10):787-791 Adlard JW Thalidomide in the treatment of cancer | 5 | 11 |
10 | 16 | 34 | 1478 2002 JOURNAL OF CARDIAC FAILURE 8(5):306-314 Agoston I; Dibbs ZI; Wang F; Muller G; Zeldis JB; Mann DL; Bozkurt B Preclinical and clinical assessment of the safety and potential efficacy of thalidomide in heart failure | 2 | 3 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
11 | 0 | 0 | 19 1981 INTERNATIONAL JOURNAL OF LEPROSY AND OTHER MYCOBACTERIAL DISEASES 49(4):512-512 AGRAWAL KC; HASSAN KM; HASTINGS RC STRUCTURE ACTIVITY RELATIONSHIP STUDIES OF THALIDOMIDE ANALOGS AS ANTI-INFLAMMATORY AND IMMUNOSUPPRESSIVE AGENTS | 0 | 0 |
12 | 0 | 0 | 1612 2003 BLOOD 102(11):237A-237A Agrawal NR; Hussein MA; Elson P; Karam MA; Reed J; Srkalovic G Pegylated Doxorubicin(D), Vineristine(V), reduced frequency Dexamethasone(D) and Thalidomide(T) (DVd-T) in newly diagnosed (Nmm) and relapsed/refractory (Rmm) multiple myeloma patients. | 0 | 0 |
13 | 0 | 0 | 1619 2003 BLOOD 102(11):378B-378B Agrawal NR; Srkalovic G; Sup S; Hsi ED; Elson P; Hussein MA Impact of pegylated doxorubicin(D), vincristine(V), reduced frequency dexamethasone(D) and thalidomide(T) {DVd-T} on bone marrow microvessel density (MVD) in newly diagnosed multiple myeloma (MM) patients (pts). | 0 | 0 |
14 | 0 | 0 | 1119 2001 BLOOD 98(11):307B-307B Ahmad I; Alam AR; Hahn T; Becker J; Chanan-Khan AA; Czuczman M; Bernstein S; Bernstein Z; McCarthy P Thalidomide plus VAD (vincristine, doxorabicin and dexamethasone) salvage therapy for VAD-refractory multiple myeloma, prior to autologous peripheral blood stem cell transplant (PBSCT). | 0 | 0 |
15 | 9 | 19 | 1394 2002 BONE MARROW TRANSPLANTATION 29(7):577-580 Ahmad I; Islam T; Chanan-Khan A; Hahn T; Wentling D; Becker JL; McCarthy PL; Alam AR Myeloma - Thalidomide as salvage therapy for VAD-refractory multiple myeloma prior to autologous PBSCT | 6 | 7 |
16 | 4 | 4 | 1757 2003 JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION 37(4):522-522 Ahmed M; El-Hadi S; Jenkins HR Thalidomide in Crohn disease and the risk of peripheral neuropathy | 0 | 0 |
17 | 0 | 1 | 1665 2003 BONE MARROW TRANSPLANTATION 31(11):1067-1067 Alam AR Thalidomide as salvage therapy for VAD-refractory multiple myeloma prior to autologous PBSCT - Reply to the letter by V Pitini | 0 | 0 |
18 | 0 | 0 | 1365 2002 BLOOD 100(11):390B-390B Alegre A; Gil-Fernandez JJ; Font P; Alonso A; Sureda A; Martinez-Chamorro C; Escudero A; Sanchez-Godoy P; Burgaleta C; Casado LF; Granda A; Aguado B; Osorio S; Nistal S; Mascunano R; Prieto E; Fernandez-Ranada JM Thalidomide as rescue of relapses after haematopoietic transplantation in multiple myeloma and as maintenance treatment: Results of a Spanish multicentre study including 63 patients. | 0 | 0 |
19 | 0 | 0 | 1121 2001 BLOOD 98(11):307B-307B Alegre A; Macias GR; Granda A; Golbano N; Martinez E; Alaez C; Blazquez C; Gongora E; Cannata J; Sanchez-Godoy P; Martinez-Chamorro C; Arranz R; de Soria VGG; Figuera A; Arranz E; Fernandez-Ranada JM Thalidomide as rescue treatment of relapses after haematopoietic transplantation in multiple myeloma. | 0 | 0 |
20 | 0 | 0 | 1865 2004 BONE MARROW TRANSPLANTATION 33:S356-S356 Alegre A; Martinez-Chamorro C; Escudero A; Aguado B; Osorio S; Nistal S; Cordoba R; Gil-Fernandez J; Sanchez-Godoy P; Burgaleta C; Casado F; Fernandez-Ranada JM Maintenance treatment with bisphosphonates plus interferon plus dexamethasone plus thalidomide (quadruple maintenance) after autologous peripheral blood stem cell transplantion in multiple myeloma: preliminary results | 0 | 0 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
21 | 8 | 16 | 566 1997 AIDS RESEARCH AND HUMAN RETROVIRUSES 13(4):301-304 Alexander LN; Wilcox CM A prospective trial of thalidomide for the treatment of HIV-associated idiopathic esophageal ulcers | 25 | 32 |
22 | 5 | 42 | 1053 2000 SEMINARS IN HEMATOLOGY 37(1):35-39 Alexanian R; Anderson KC; Barlogie B; Stirling DI; Thomas DA Thalidomide in hematologic malignancies: Future directions | 5 | 5 |
23 | 0 | 10 | 1051 2000 SEMINARS IN HEMATOLOGY 37(1):22-25 Alexanian R; Weber D Thalidomide for resistant and relapsing myeloma | 23 | 27 |
24 | 12 | 17 | 1819 2003 SEMINARS IN HEMATOLOGY 40(4):3-7 Alexanian R; Weber D; Anagnostopoulos A; Delasalle K; Wang M; Rankin K Thalidomide with or without dexamethasone for refractory or relapsing multiple myeloma | 0 | 0 |
25 | 3 | 14 | 1295 2002 ANNALS OF ONCOLOGY 13(7):1116-1119 Alexanian R; Weber D; Giralt S; Delasalle K Consolidation therapy of multiple myeloma with thalidomide-dexamethasone after intensive chemotherapy | 7 | 10 |
26 | 0 | 0 | 1106 2001 BLOOD 98(11):163A-163A Alexanian R; Weber DM; Giralt S; Delasalle KB Consolidation therapy of multiple myeloma with thalidomide-dexamethasone after intensive chemotherapy. | 0 | 2 |
27 | 9 | 12 | 1764 2003 JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY 48(5):S89-S91 Alfadley A; Al Rayes H; Hussein W; Al Dalaan A; Al-Aboud K Thalidomide for treatment of severe generalized discoid lupus lesions in two patients with systemic lupus erythematosus | 0 | 0 |
28 | 11 | 39 | 1731 2003 INTERNATIONAL JOURNAL OF DERMATOLOGY 42(5):372-375 Alfadley A; Al-Hawsawi K; Thestrup-Pedersen K; Al-Aboud K Treatment of prurigo nodularis with thalidomide: a case report and review of the literature | 0 | 0 |
29 | 6 | 12 | 1148 2001 BRITISH JOURNAL OF DERMATOLOGY 144(2):227-228 Allen BR Thalidomide | 4 | 4 |
30 | 5 | 15 | 956 2000 CHROMATOGRAPHIA 52(7-8):455-458 Alvarez C; Sanchez-Brunete JA; Torrado-Santiago S; Cadorniga R; Torrado JJ Enantioselective separation of thalidomide on on immobilized alpha(l)-acid glycoprotein chiral stationary phase | 0 | 2 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
31 | 0 | 0 | 1349 2002 BLOOD 100(11):375A-375A Alvi S; Borok RZ; Shaher A; Anthwal S; Shaikh M; Alvi I; Tahir S; John P; Shetty V; Galili N; Raza A Thalidomide significantly modifies bone marrow microenvironment in myelodysplastic syndrome (MDS) patients. | 0 | 0 |
32 | 0 | 0 | 927 2000 BLOOD 96(11):356A-356A Alvi S; Henderson B; Shaher A; Dangerfield B; Broderick E; Jafri N; Tareen M; Du Randt M; Galili N; Borok RZ; Raza A Determination of clonality in stromal and parenchymal cells pre and post thalidomide treatment in myelodysplasia. | 0 | 0 |
33 | 0 | 0 | 928 2000 BLOOD 96(11):359A-359A Alvi S; Shaher A; Henderson B; Dar S; Zorat F; Broderick E; Lisak L; Du Randt M; Reddy P; Mundle S; Galili N; Borok RZ; Raza A Improved growth of stromal cells in long term bone marrow cultures (LTBMC) of myelodysplastic syndrome (MDS) patients treated with thalidomide. | 0 | 1 |
34 | 0 | 0 | 1128 2001 BLOOD 98(11):351A-352A Alvi S; Shaher A; Shaikh M; Anthwal S; Siddiqi F; Akhtar A; Ashraf H; Meagher R; Mundle S; Shetty V; Goldberg C; Galili N; Borok RZ; Raza A MDS patients with hematological response to thalidomide show enhanced in vitro growth potential. | 0 | 0 |
35 | 0 | 0 | 1129 2001 BLOOD 98(11):352A-352A Alvi S; Shaikh M; Anthwal S; Shaher A; Tamoseviciene D; Novick A; Reddy P; Allampallam K; Hsu WT; Galili N; Borok RZ; Raza A Cytogenetic and clonal profile of myelodysplastic syndromes (MDS) patients treated with thalidomide. | 0 | 0 |
36 | 7 | 18 | 1042 2000 ONCOLOGY-NEW YORK 14(12):33-36 Amato R Thalidomide for recurrent renal-cell cancer in a 40-year-old man | 2 | 2 |
37 | 13 | 38 | 1708 2003 CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY 46:S59-S65 Amato RJ Thalidomide therapy for renal cell carcinoma | 0 | 1 |
38 | 0 | 0 | 1641 2003 BLOOD 102(11):454A-454A Anagnostopoulos A; Efstathiou E; Hamilos G; Zorzou MP; Kastritis E; Dimopoulos MA Patterns of progression in myeloma patients treated with thalidomide-based regimens: High incidence of extramedullary progression without serologic relapse. | 0 | 0 |
39 | 0 | 0 | 680 1998 BONE MARROW TRANSPLANTATION 21:S113-S113 Anagnostopoulos A; Fassas A; Giannaki E; Sakellari I; Tzarou V; Smias C; Lalayanni C; Papaioannou G; Gakos E Treatment of resistant chronic GVHD with thalidomide. | 0 | 0 |
40 | 10 | 18 | 1947 2004 LEUKEMIA & LYMPHOMA 45(1):113-116 Anagnostopoulos A; Hamilos G; Zorzou MP; Grigoraki V; Anagnostou D; Dimopoulos MA Discordant response or progression in patients with myeloma treated with thalidomide-based regimens | 0 | 0 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
41 | 4 | 12 | 1679 2003 BRITISH JOURNAL OF HAEMATOLOGY 121(5):768-771 Anagnostopoulos A; Weber D; Rankin K; Delasalle K; Alexanian R Thalidomide and dexamethasone for resistant multiple myeloma | 11 | 16 |
42 | 0 | 0 | 1659 2003 BLOOD 102(11):938A-938A Anagnostopoulos A; Zervas K; Zomas A; Pouli A; Hamilos G; Anagnostopoulos N; Dimopoulos MA The International Prognostic Index (IPI) is predictive for survival in refractory or relapsed myeloma patients treated with thalidomide-based regimens. | 0 | 0 |
43 | 0 | 0 | 1642 2003 BLOOD 102(11):454A-454A Anaissie EJ; Jacobson J; Fassas AB; Zangari M; Thertulien R; VanRhee F; Talamo G; Tricot G; Wendling C; Davis CK; Hollmig K; Barlogie B Safety of total therapy II with or without thalidomide (THAL) for newly diagnosed myeloma: A study of 475 consecutive patients. | 0 | 0 |
44 | 4 | 11 | 1535 2002 OBSTETRICS AND GYNECOLOGY 99(1):125-128 Ances BM New concerns about thalidomide | 1 | 3 |
45 | 0 | 0 | 1097 2001 BLOOD 98(11):52B-52B Anders O; Plath F; Emmrich J; Freund M Complete remission of therapy-resistant angiodysplasia of the stomach in myelodysplastic syndrome following thalidomide. | 0 | 0 |
46 | 9 | 27 | 1048 2000 SEMINARS IN HEMATOLOGY 37(1):1-4 Anderson KC Thalidomide: Therapeutic potential in hematologic malignancies | 6 | 8 |
47 | 16 | 29 | 1413 2002 CANCER BIOLOGY & THERAPY 1(6):669-673 Ando L; Price DK; Dahut WL; Cox MC; Reed E; Figg WD Pharmacogenetic associations of CYP2C19 genotype with in vivo metabolisms and pharmacological effects of thalidomide | 0 | 0 |
48 | 25 | 54 | 1425 2002 CLINICAL CANCER RESEARCH 8(6):1964-1973 Ando Y; Fuse E; Figg WD Thalidomide metabolism by the CYP2C subfamily | 14 | 15 |
49 | 0 | 0 | 1547 2002 PHARMACOTHERAPY 22(10):1362-1362 Ando Y; Price DK; Dahut WL; Cox MC; Reed E; Figg WD Pharmacogenetics of thalidomide: drug response, in vivo metabolism and genetic polymorphism of CYP2C19. | 0 | 0 |
50 | 1 | 6 | 1789 2003 LEUKEMIA & LYMPHOMA 44(6):1081-1082 Andretta C; Catalano L; Pace L; Fonti R; Annunziata G; Rotoli B 99mTc-sestaMIBI scintigraphy in thalidomide-treated refractory or relapsed multiple myeloma patients | 0 | 1 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
51 | 6 | 24 | 748 1999 AMERICAN JOURNAL OF PUBLIC HEALTH 89(1):98-101 Annas GJ; Elias S Thalidomide and the Titanic: Reconstructing the technology tragedies of the twentieth century | 5 | 7 |
52 | 15 | 16 | 1966 2004 NEUROLOGY 62(12):2158-2159 Apfel SC; Zochodne DW Thalidomide neuropathy - Too much or too long? | 0 | 0 |
53 | 16 | 45 | 426 1994 SCANDINAVIAN JOURNAL OF IMMUNOLOGY 40(5):535-542 ARALACHAVES M; VILANOVA M; RIBEIRO A; PINTO J IMMUNOSTIMULATORY EFFECT OF THALIDOMIDE IN NORMAL C57BL/6 MICE IS COMPATIBLE WITH STIMULATION OF A HIGHLY CONNECTED CENTRAL IMMUNE-SYSTEM .1. | 4 | 6 |
54 | 13 | 66 | 727 1998 MEDICAL HYPOTHESES 50(4):313-318 Argiles JM; Carbo N; Lopez-Soriano FJ Was tumour necrosis factor-alpha responsible for the fetal malformations associated with thalidomide in the early 1960s? | 11 | 12 |
55 | 0 | 0 | 132 1984 TERATOLOGY 30(1):A36-A36 ARIMOTO H OCULAR FINDINGS OF THALIDOMIDE EMBRYOPATHY | 0 | 0 |
56 | 0 | 0 | 1098 2001 BLOOD 98(11):52B-52B Arkel YS; Ku DHW; Le P Effect of thalidomide on tissue factor activity in monocytic and endothelial cell lines, and relationship to tumor necrosis factor-alpha (TNF). | 0 | 0 |
57 | 8 | 12 | 1770 2003 JOURNAL OF THROMBOSIS AND HAEMOSTASIS 1(12):2691-2692 Arkel YS; Ku DHW; Thurston AL The effect of thalidomide on tissue factor activity in Mono Mac 6 cells and the relationship to tumor necrosis factor (TNF)- alpha-stimulated cells | 0 | 0 |
58 | 5 | 76 | 544 1996 JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS 277(3):1649-1658 Arlen RR; Wells PG Inhibition of thalidomide teratogenicity by acetylsalicylic acid: Evidence for prostaglandin H synthase-catalyzed bioactivation of thalidomide to a teratogenic reactive intermediate | 9 | 15 |
59 | 3 | 10 | 188 1986 JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY 14(2):282-283 ARONSON IK; WEBER L; WEST D; BUYS C; REDER A; ANTEL J THALIDOMIDE AND LYMPHOCYTE FUNCTION | 6 | 6 |
60 | 3 | 35 | 107 1984 ARCHIVES OF DERMATOLOGY 120(11):1466-1470 ARONSON IK; YU R; WEST DP; VANDENBROEK H; ANTEL J THALIDOMIDE-INDUCED PERIPHERAL NEUROPATHY - EFFECT OF SERUM FACTOR ON NERVE CULTURES | 35 | 39 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
61 | 0 | 0 | 112 1984 CLINICAL RESEARCH 32(2):A569-A569 ARONSON IK; YU R; WEST DP; VANDENBROEK H; ANTEL J THALIDOMIDE INDUCED PERIPHERAL NEUROPATHY - EFFECT OF SERUM FACTOR ON NERVE CULTURES | 0 | 0 |
62 | 4 | 18 | 1088 2001 BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION 7(5):265-273 Arora M; Wagner JE; Davies SM; Blazar BR; Defor T; Enright H; Miller WF; Weisdorf DJ Randomized clinical trial of thalidomide, cyclosporine, and prednisone versus cyclosporine and prednisone as initial therapy for chronic graft-versus-host disease | 8 | 15 |
63 | 27 | 44 | 1472 2002 INTERNATIONAL JOURNAL OF EXPERIMENTAL PATHOLOGY 83(2):99-104 Arrieta O; Guevara P; Tamariz J; Rembao D; Rivera E; Sotelo J Antiproliferative effect of thalidomide alone and combined with carmustine against C6 rat glioma | 1 | 3 |
64 | 4 | 24 | 817 1999 INTERNATIONAL JOURNAL OF EXPERIMENTAL PATHOLOGY 80(1):11-16 Arrieta O; Ortiz-Reyes A; Rembao D; Calvillo M; Rivera E; Sotelo J Protective effect of pentoxifylline plus thalidomide against septic shock in mice | 4 | 8 |
65 | 3 | 38 | 1866 2004 BRAZILIAN JOURNAL OF MEDICAL AND BIOLOGICAL RESEARCH 37(4):485-492 Arruda MSP; Richini VB; Oliveira SMA; Vilani-Moreno FR Experimental murine mycobacteriosis: evaluation of the functional activity of alveolar macrophages in thalidomide-treated mice | 0 | 0 |
66 | 2 | 15 | 194 1986 REVISTA DO INSTITUTO DE MEDICINA TROPICAL DE SAO PAULO 28(1):12-14 ARRUDA WO; HACBARTH E; DOI E; SANTAMARIA JR; BARBOSA J; KAJDACSYBALLA AA EFFECT OF THALIDOMIDE ON SERUM LEVELS OF IMMUNOGLOBULINS IGM AND IGA, RHEUMATOID-FACTOR AND ISOHEMAGLUTININS ANTI-A AND ANTI-B IN PATIENTS WITH LEPROMATOUS LEPROSY - A DOUBLE-BLIND-STUDY | 1 | 2 |
67 | 5 | 35 | 605 1997 IMMUNOPHARMACOLOGY AND IMMUNOTOXICOLOGY 19(3):313-326 Aseffa A; Dietrich MA; Shannon EJ Effect of thalidomide on apoptosis of lymphocytes and neutrophils | 4 | 5 |
68 | 2 | 5 | 637 1997 NATURE 389(6647):118-118 Ashby J Thalidomide is not a mutagen | 3 | 4 |
69 | 4 | 11 | 480 1995 NATURE 375(6531):453-453 ASHBY J; TINWELL H IS THALIDOMIDE MUTAGENIC | 7 | 11 |
70 | 5 | 5 | 1410 2002 BRITISH MEDICAL JOURNAL 325(7374):1245-1245 Ashby J; Tinwell H Thalidomide is not a human mutagen | 0 | 0 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
71 | 8 | 59 | 635 1997 MUTATION RESEARCH-FUNDAMENTAL AND MOLECULAR MECHANISMS OF MUTAGENESIS 396(1-2):45-64 Ashby J; Tinwell H; Callander RD; Kimber I; Clay P; Galloway SM; Hill RB; Greenwood SK; Gaulden ME; Ferguson MJ; Vogel E; Nivard M; Parry JM; Williamson J Thalidomide: lack of mutagenic activity across phyla and genetic endpoints | 12 | 14 |
72 | 1 | 3 | 394 1994 BRITISH MEDICAL JOURNAL 309(6948):193-194 ASSCHER W SAFETY OF THALIDOMIDE | 2 | 2 |
73 | 17 | 33 | 359 1993 CLINICAL AND EXPERIMENTAL RHEUMATOLOGY 11(5):487-493 ATRA E; SATO EI TREATMENT OF THE CUTANEOUS LESIONS OF SYSTEMIC LUPUS-ERYTHEMATOSUS WITH THALIDOMIDE | 47 | 65 |
74 | 2 | 30 | 418 1994 MIKROCHIMICA ACTA 117(1-2):75-85 AUCELIO RQ; CAMPIGLIA AD PHARMACEUTICAL FORMULATION ANALYSIS OF THALIDOMIDE BY SOLID-SURFACE ROOM-TEMPERATURE PHOSPHORIMETRY | 1 | 10 |
75 | 5 | 32 | 385 1994 BIOGENIC AMINES 10(6):543-554 AUDIT CO THALIDOMIDE-INDUCED POLYAMINE ACYLATION - A NEW INSIGHT INTO THE ACYLATION MECHANISM | 3 | 3 |
76 | 3 | 65 | 510 1996 BIOGENIC AMINES 12(4):305-326 Audit CO Specific functions of polyamines: Actin assembly, cytokinesis induction, targets for thalidomide activity, nitrogen sources for marine ecosystems | 1 | 3 |
77 | 5 | 6 | 633 1997 M S-MEDECINE SCIENCES 13(4):595-596 Audit CO; Aimar C Thalidomide-induced teratogenesis. | 0 | 0 |
78 | 11 | 39 | 522 1996 DEVELOPMENT GROWTH & DIFFERENTIATION 38(1):47-57 Audit CO; Eger K; Aimar C Possible involvement of an acylation mechanism in thalidomide-induced teratogenesis of the newt (Pleurodeles waltl) | 2 | 2 |
79 | 2 | 18 | 1419 2002 CHEMICAL COMMUNICATIONS (19):2242-2243 Augusti DV; Augusti R; Carazza F; Cooks RG Quantitative determination of the enantiomeric composition of thalidomide solutions by electrospray ionization tandem mass spectrometry | 0 | 0 |
80 | 0 | 1 | 630 1997 LANCET 350(9081):873-873 Ault A Thalidomide comes close to US approval | 1 | 1 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
81 | 0 | 0 | 724 1998 LANCET 352(9124):298-298 Ault A Thalidomide makes a return to US health care | 0 | 0 |
82 | 10 | 60 | 1833 2004 ALIMENTARY PHARMACOLOGY & THERAPEUTICS 19(1):79-88 Austin AS; Mahida YR; Clarke D; Ryder SD; Freeman JG A pilot study to investigate the use of oxpentifylline (pentoxifylline) and thalidomide in portal hypertension secondary to alcoholic cirrhosis | 0 | 0 |
83 | 0 | 0 | 1197 2001 GUT 48:A67-A68 Austin AS; Mahida YR; Ryder SD; Freeman JG Thalidomide but not pentoxifylline lowers portal pressure in human alcoholic cirrhosis | 0 | 0 |
84 | 0 | 0 | 1227 2001 JOURNAL OF HEPATOLOGY 34:18-18 Austin AS; Mahida YR; Ryder SD; Freeman JG Thalidomide but not pentoxifylline lowers portal pressure in human alcoholic cirrhosis | 0 | 0 |
85 | 0 | 0 | 1126 2001 BLOOD 98(11):311B-311B Avalos JS; Barazzutti L; Korin J; Kusminsky G; Ferro H; Tavella O; Foncuberta M; Tartas N Thalidomide and cranial nerves neuropathies. | 0 | 0 |
86 | 4 | 18 | 139 1985 ARCHIVOS DE INVESTIGACION MEDICA 16(2):139-143 AVALOSDIAZ E; GUZMANENRIQUEZ L; LOPEZROBLES E; HERRERAESPARZA R INHIBITORY EFFECT OF ENDOCYTOSIS IN POLIMORPHONUCLEAR CELLS CAUSED BY THALIDOMIDE | 0 | 0 |
87 | 8 | 17 | 1240 2001 LEUKEMIA & LYMPHOMA 42(4):683-+ Avigdor A; Raanani P; Levi I; Hardan I; Ben-Bassat I Extramedullary progression despite a good response in the bone marrow in patients treated with thalidomide for multiple myeloma | 8 | 9 |
88 | 11 | 18 | 1225 2001 JOURNAL OF CLINICAL PHARMACOLOGY 41(10):1091-1097 Aweeka F; Trapnell C; Chernoff M; Jayewardene A; Spritzler J; Bellibas SE; Lizak P; Jacobson J Pharmacokinetics and pharmacodynamics of thalidomide in HIV patients treated for oral aphthous ulcers: ACTG protocol 251 | 6 | 7 |
89 | 0 | 0 | 342 1992 TROPICAL DOCTOR 22(3):139-139 AWOFESO N THALIDOMIDE PERIPHERAL NEUROPATHY | 1 | 4 |
90 | 1 | 3 | 110 1984 BRITISH JOURNAL OF DERMATOLOGY 111(1):125-126 AYRES S THALIDOMIDE OR VITAMIN-E THERAPY FOR DISCOID LUPUS-ERYTHEMATOSUS | 1 | 2 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
91 | 1 | 4 | 152 1985 INTERNATIONAL JOURNAL OF DERMATOLOGY 24(9):616-616 AYRES S DISCOID LUPUS-ERYTHEMATOSUS - THALIDOMIDE OR VITAMIN-E | 0 | 1 |
92 | 0 | 0 | 1701 2003 CLINICAL CANCER RESEARCH 9(16):6150S-6150S Baas P; Haringhuizen A; Boogerd W; Dalesio O; Van Zandwijk N Thalidomide in malignant pleural mesothelioma: Results of a phase II study. | 0 | 0 |
93 | 23 | 55 | 1257 2001 OPHTHALMIC RESEARCH 33(5):256-263 Baatz H; Tonessen B; Prada J; Pleyer U Thalidomide inhibits leukocyte-endothelium interaction in endotoxin-induced uveitis | 1 | 4 |
94 | 0 | 0 | 613 1997 INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE 38(4):5409-5409 Baatz H; Tonnessen B; Pleyer U; Hartmann C Thalidomide inhibits leukocyte-endothelium-interaction in endotoxin-induced uveitis | 0 | 0 |
95 | 0 | 0 | 720 1998 JOURNAL OF VASCULAR RESEARCH 35:54-54 Baatz H; Tonnessen B; Pleyer U; Hartmann C Antiinflammatory action of thalidomide: Modulation of leukocyte-endothelium interaction | 0 | 0 |
96 | 5 | 23 | 1522 2002 LEUKEMIA & LYMPHOMA 43(6):1267-1271 Badros A; Morris C; Zangari M; Barlogie B; Tricot G Thalidomide paradoxical effect on concomitant multiple myeloma and myelodysplasia | 3 | 3 |
97 | 0 | 0 | 911 2000 BLOOD 96(11):285B-285B Badros A; Zangari M; Bodenner D; Siegel E; Spoon D; Toor A; Desikan R; Arnold E; Anaissie E; Zeldis J; Tricot G; Barlogie B Hypothyroidism in patients with multiple myeloma (MM) receiving thalidomide. | 0 | 3 |
98 | 0 | 0 | 1648 2003 BLOOD 102(11):684A-684A Badros AZ; Ratterree B; Natt S; Rapoport AP; Zeldis JB; Frankel SR; Meisenberg B; Takebe N; Zwiebel JA; Zhang B; Fenton R Phase I/II trial of oblimersen sodium (G3139), dexamethasone (Dex) and thalidomide (Thal) in patients with relapsed multiple myeloma. | 0 | 1 |
99 | 5 | 16 | 1289 2002 AMERICAN JOURNAL OF MEDICINE 112(5):412-413 Badros AZ; Siegel E; Bodenner D; Zangari M; Zeldis J; Barlogie B; Tricot G Hypothyroidism in patients with multiple myeloma following treatment with thalidomide | 9 | 10 |
100 | 0 | 0 | 1368 2002 BLOOD 100(11):393A-393A Bahlis NJ; Sawney R; Gerson S PKC delta inhibition induces cell death in thalidomide and dexamethasone resistant multiple myeloma cell lines. | 0 | 0 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
101 | 0 | 7 | 36 1982 ACTA DERMATO-VENEREOLOGICA 62(5):449-450 BAHMER FA; ZAUN H; LUSZPINSKI P THALIDOMIDE TREATMENT OF RECURRENT ERYTHEMA MULTIFORME | 19 | 25 |
102 | 80 | 118 | 1415 2002 CANCER INVESTIGATION 20(5-6):835-848 Baidas S; Tfayli A; Bhargava P Thalidomide: An old drug with new clinical applications | 1 | 3 |
103 | 21 | 40 | 1005 2000 JOURNAL OF CLINICAL ONCOLOGY 18(14):2710-2717 Baidas SM; Winer EP; Fleming GF; Harris L; Pluda JM; Crawford JG; Yamauchi H; Isaacs C; Hanfelt J; Tefft M; Flockhart D; Johnson MD; Hawkins MJ; Lippman ME; Hayes DF Phase II evaluation of thalidomide in patients with metastatic breast cancer | 39 | 54 |
104 | 4 | 13 | 1948 2004 LEUKEMIA & LYMPHOMA 45(1):179-181 Baird R; van Zyl-Smit RN; Iveson A; Duddy J; Rassam S Thalidomide is highly effective in a patient with meningeal acute myeloid leukaemia | 0 | 0 |
105 | 0 | 0 | 1130 2001 BLOOD 98(11):353A-354A Baker AF; Bellamy WT; Glinsmann-Gibson BJ; Heaton R; Buresh A; Grogan TM; List AF Biological response to thalidomide in remitting patients with myelodysplastic syndrome (MDS): Evidence for induction of neoplastic vascular endothelial growth factor (VEGF) resistance. | 0 | 0 |
106 | 10 | 11 | 570 1997 AMERICAN JOURNAL OF GASTROENTEROLOGY 92(1):169-170 Ball SC; Sepkowitz KA; Jacobs JL Thalidomide for treatment of oral aphthous ulcers in patients with human immunodeficiency virus: Case report and review | 12 | 13 |
107 | 14 | 20 | 1949 2004 LEUKEMIA & LYMPHOMA 45(4):735-738 Balleari E; Ghio R; Falcone A; Musto P Possible multiple myeloma dedifferentiation following thalidomide therapy: A report of four cases | 0 | 0 |
108 | 0 | 0 | 1606 2003 BLOOD 102(11):56B-56B Ballester G; Ballester O; Daitch L; Kutlar A Response to thalidomide therapy in multicentric Castleman's disease. | 0 | 0 |
109 | 6 | 10 | 1768 2003 JOURNAL OF THROMBOSIS AND HAEMOSTASIS 1(3):421-422 Barbui T; Falanga A Thalidomide and thrombosis in multiple myeloma | 2 | 2 |
110 | 13 | 25 | 1492 2002 JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY 17(2):135-139 Bariol C; Meagher AP; Vickers CR; Byrnes DJ; Edwards PD; Hing M; Wettstein AR; Field A Early studies on the safety and efficacy of thalidomide for symptomatic inflammatory bowel disease | 8 | 13 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
111 | 1 | 4 | 1032 2000 NEW ENGLAND JOURNAL OF MEDICINE 342(13):975-976 Barlogie B Thalidomide in multiple myeloma - Reply | 0 | 0 |
112 | 7 | 20 | 1818 2003 SEMINARS IN HEMATOLOGY 40(4):1-2 Barlogie B Introduction: Thalidomide and the IMiDs in multiple myeloma | 0 | 0 |
113 | 11 | 14 | 1822 2003 SEMINARS IN HEMATOLOGY 40(4):33-38 Barlogie B Thalidomide and CC-5013 in multiple myeloma: The University of Arkansas experience | 0 | 0 |
114 | 9 | 21 | 1094 2001 BLOOD 98(2):492-494 Barlogie B; Desikan R; Eddlemon P; Spencer T; Zeldis J; Munshi N; Badros A; Zangari M; Anaissie E; Epstein J; Shaughnessy J; Ayers D; Spoon D; Tricot G Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients | 68 | 113 |
115 | 0 | 0 | 934 2000 BLOOD 96(11):514A-514A Barlogie B; Spencer T; Tricot G; Zeldis J; Munshi N; Zangari M; Badros A; Toor A; Shaughnessy J; Morris C; Desikan R Long term follow up of 169 patients receiving a phase II trial of single agent thalidomide for advanced and refractory multiple myeloma (MM). | 0 | 14 |
116 | 7 | 18 | 1270 2001 SEMINARS IN ONCOLOGY 28(6):577-582 Barlogie B; Tricot G; Anaissie E Thalidomide in the management of multiple myeloma | 10 | 17 |
117 | 0 | 0 | 1337 2002 BLOOD 100(11):210A-210A Barlogie B; Tricot G; Anaissie E; Fassas A; Lee CK; Thertulien R; van Rhee F; Zangari M Long-term follow-up (median of 4 yr) of 169 patients receiving thalidomide (THAL) for advanced and refractory multiple myeloma (MM): Superior survival in the absence of cytogenetic abnormalities (CA) and low beta-2 microglobulin (B2M). | 0 | 0 |
118 | 6 | 48 | 1268 2001 SEMINARS IN HEMATOLOGY 38(3):250-259 Barlogie B; Zangari M; Spencer T; Fassas A; Anaissie E; Badros A; Cromer J; Tricot G Thalidomide in the management of multiple myeloma | 18 | 31 |
119 | 0 | 0 | 1238 2001 LEUKEMIA 15(3):491-491 Barlogie D; Spencer T; Tricot G; Zeldis J; Munshi N; Zangari M; Badros A; Toor A; Shaughnessy J; Morris C; Desikan R Long term follow up of 169 patients receiving a phase II trial of single agent thalidomide for advanced and refractory multiple myeloma (MM). | 0 | 0 |
120 | 0 | 0 | 548 1996 LANCET 348(9038):1370-1370 Barnett AA FDA encourages firms to test thalidomide | 0 | 0 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
121 | 0 | 0 | 629 1997 LANCET 349(9045):111-111 Barnett AA Company applies to market thalidomide in USA | 0 | 0 |
122 | 1 | 3 | 158 1985 JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY 13(2):305-305 BARNHILL RL THALIDOMIDE AND OXYGEN INTERMEDIATES - REPLY | 0 | 0 |
123 | 8 | 39 | 119 1984 JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY 11(5):814-819 BARNHILL RL; DOLL NJ; MILLIKAN LE; HASTINGS RC STUDIES ON THE ANTI-INFLAMMATORY PROPERTIES OF THALIDOMIDE - EFFECTS ON POLYMORPHONUCLEAR LEUKOCYTES AND MONOCYTES | 44 | 50 |
124 | 2 | 54 | 48 1982 JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY 7(3):317-323 BARNHILL RL; MCDOUGALL AC THALIDOMIDE - USE AND POSSIBLE MODE OF ACTION IN REACTIONAL LEPROMATOUS LEPROSY AND IN VARIOUS OTHER CONDITIONS | 84 | 111 |
125 | 0 | 0 | 1383 2002 BLOOD 100(11):800A-800A Barosi G; Elliott M; Canepa L; Ballerini F; Piccaluga PP; Visani G; Marchetti M; Pozzato G; Zorat F; Tefferi A Thalidomide in Myelofibrosis with Myeloid Metaplasia: A pooled-analysis of individual patient data from five studies. | 0 | 0 |
126 | 0 | 0 | 939 2000 BLOOD 96(11):746A-746A Barosi G; Grossi A; Comotti B; Marchetti M Thalidomide in patients with myelofibrosis with myeloid metaplasia. | 0 | 4 |
127 | 12 | 22 | 1152 2001 BRITISH JOURNAL OF HAEMATOLOGY 114(1):78-83 Barosi G; Grossi A; Comotti B; Musto P; Gamba G; Marchetti M Safety and efficacy of thalidomide in patients with myelofibrosis with myeloid metaplasia | 13 | 24 |
128 | 0 | 2 | 94 1983 PRESSE MEDICALE 12(15):963-963 BARRIERE H SARCOIDOSIS OF THE SKIN - TREATMENT WITH THALIDOMIDE | 12 | 16 |
129 | 0 | 0 | 1079 2001 ARTHRITIS AND RHEUMATISM 44(9):S125-S125 Barthel HR Successful treatment of Weber Christian disease (WCD) with thalidomide in a patient failing multiple other medical therapies | 0 | 0 |
130 | 4 | 40 | 1477 2002 JCR-JOURNAL OF CLINICAL RHEUMATOLOGY 8(5):256-259 Barthel HR; Charrier U; Kramer M; Loch C Successful treatment of idiopathic febrile panniculitis (Weber-Christian disease) with thalidomide in a patient having failed multiple other medical therapies | 0 | 0 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
131 | 39 | 57 | 1965 2004 NATURE REVIEWS CANCER 4(4):314-322 Bartlett JB; Dredge K; Dalgleish AG Timeline - The evolution of thalidomide and its IMiD derivatives as anticancer agents | 2 | 2 |
132 | 32 | 40 | 1867 2004 BRITISH JOURNAL OF CANCER 90(5):955-961 Bartlett JB; Michael A; Clarke IA; Dredge K; Nicholson S; Kristeleit H; Polychronis A; Pandha H; Muller GW; Stirling DI; Zeldis J; Dalgleish AG Phase 1 study to determine the safety, tolerability and immunostimulatory activity of thalidomide analogue CC-5013 in patients with metastatic malignant melanoma and other advanced cancers | 1 | 1 |
133 | 3 | 10 | 1566 2003 AMERICAN JOURNAL OF HEMATOLOGY 74(3):205-207 Barton JC Thalidomide and dexamethasone therapy of myeloma in a patient with previously untreated B-chronic lymphocytic leukemia | 0 | 0 |
134 | 17 | 24 | 1499 2002 JOURNAL OF INVESTIGATIVE DERMATOLOGY 119(5):1020-1026 Bastuji-Garin S; Ochonisky S; Bouche P; Gherardi RK; Duguet C; Djerradine Z; Poli F; Revuz J; Thalidomide Neuropathy Study Grp Incidence and risk factors for thalidomide neuropathy: a prospective study of 135 dermatologic patients | 9 | 12 |
135 | 6 | 21 | 1907 2004 GUT 53(4):609-612 Bauditz J; Schachschal G; Wedel S; Lochs H Thalidomide for treatment of severe intestinal bleeding | 0 | 0 |
136 | 0 | 0 | 1453 2002 GASTROENTEROLOGY 122(4):A194-A194 Bauditz J; Wedel S; Lochs H Thalidomide for treatment of intestinal bleeding: Correlation to VEGF | 1 | 1 |
137 | 13 | 36 | 1458 2002 GUT 50(2):196-200 Bauditz J; Wedel S; Lochs H Thalidomide reduces tumour necrosis factor alpha and interleukin 12 production in patients with chronic active Crohn's disease | 11 | 25 |
138 | 0 | 0 | 979 2000 GASTROENTEROLOGY 118(4):A580-A580 Bauditz L; Wedel S; Suk A; Lochs H Cytokine profiles under treatment with Thalidomide steroid-resistant Crohn's disease. | 0 | 0 |
139 | 4 | 5 | 1401 2002 BRITISH JOURNAL OF HAEMATOLOGY 117(4):996-997 Bauduer F Efficacy of thalidomide in the treatment of VAD-refractory plasma cell leukaemia appearing after autologous stem cell transplantation for multiple myeloma | 0 | 0 |
140 | 9 | 42 | 1751 2003 JOURNAL OF INTERFERON AND CYTOKINE RESEARCH 23(1):3-10 Bauer JA; Morrison BH; Grane RW; Jacobs BS; Borden EC; Lindner DJ IFN-alpha 2b and thalidomide synergistically inhibit tumor-induced angiogenesis | 0 | 2 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
141 | 11 | 27 | 670 1998 BIOCHEMICAL PHARMACOLOGY 55(11):1827-1834 Bauer KS; Dixon SC; Figg WD Inhibition of angiogenesis by thalidomide requires metabolic activation, which is species-dependent | 82 | 122 |
142 | 14 | 29 | 1420 2002 CHEST 122(1):227-232 Baughman RP; Judson MA; Teirstein AS; Moller DR; Lower EE Thalidomide for chronic sarcoidosis | 4 | 27 |
143 | 0 | 1 | 357 1993 CHEMICAL & ENGINEERING NEWS 71(28):5-5 BAUM R THALIDOMIDE BLOCKS VIRUS THAT CAUSES AIDS | 0 | 0 |
144 | 8 | 30 | 1932 2004 JOURNAL OF NEURO-ONCOLOGY 67(1-2):191-200 Baumann F; Bjeljac M; Kollias SS; Baumert BG; Brandner S; Rousson V; Yonekawa Y; Bernays RL Combined thalidomide and temozolomide treatment in patients with glioblastoma multiforme | 0 | 0 |
145 | 0 | 6 | 97 1983 TERATOLOGY 27(2):A29-A30 BECK SL PAUCITY OF POSTNATAL EFFECTS ON CD-1 MOUSE SKELETON OF PRENATAL EXPOSURE TO CAPTAN, THALIDOMIDE, CORTISONE, OR DIPHENYLHYDANTOIN | 0 | 3 |
146 | 12 | 44 | 1007 2000 JOURNAL OF INFECTIOUS DISEASES 181(3):954-965 Bekker LG; Haslett P; Maartens G; Steyn L; Kaplan G Thalidomide-induced antigen-specific immune stimulation in patients with human immunodeficiency virus type 1 and tuberculosis | 18 | 27 |
147 | 1 | 1 | 1008 2000 JOURNAL OF INFECTIOUS DISEASES 181(4):1521-1521 Bekker LG; Haslett P; Maartens G; Steyn L; Kaplan G Thalidomide-induced antigen-specific immune stimulation in patients with human immunodeficiency virus type 1 and tuberculosis. (vol 181, pg 954, 2000) | 0 | 0 |
148 | 0 | 0 | 276 1990 GAZETTE MEDICALE 97(3):26-27 BELAICH S USE OF THALIDOMIDE IN DERMATOLOGY | 0 | 0 |
149 | 4 | 38 | 96 1983 SEMAINE DES HOPITAUX 59(45):3101-3104 BELAUBE P; GARCIN G; MARCHAND JP; PRIVAT Y SHOULD THALIDOMIDE BE REHABILITATED | 4 | 7 |
150 | 8 | 14 | 527 1996 GASTROINTESTINAL ENDOSCOPY 44(6):729-731 Bellomo A; SchorrLesnick B Thalidomide treatment for idiopathic esophageal ulcers in patients with HIV | 0 | 1 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
151 | 18 | 36 | 1212 2001 INFLAMMATION 25(2):91-96 Belo AV; Ferreira MAND; Bosco AA; Machado RDP; Andrade SP Differential effects of thalidomide on angiogenesis and tumor growth in mice | 0 | 2 |
152 | 11 | 27 | 1290 2002 AMERICAN JOURNAL OF MEDICINE 113(7):603-606 Bennett CL; Schumock GT; Desai AA; Kwaan HC; Raisch DW; Newlin R; Stadler W Thalidomide-associated deep vein thrombosis and pulmonary embolism | 3 | 6 |
153 | 0 | 0 | 1141 2001 BLOOD 98(11):863A-863A Bennett CL; Schumok GT; Kwaan HC; Raisch DW High incidence of thalidomide-associated deep vein thrombosis and pulmonary emboli when chemotherapy is also administered. | 0 | 3 |
154 | 1 | 5 | 1220 2001 JOURNAL OF CHEMICAL EDUCATION 78(6):759-761 Bennett N; Cornely K Thalidomide makes a comeback: A case discussion exercise that integrates biochemistry and organic chemistry | 0 | 3 |
155 | 1 | 6 | 316 1992 ANNALES DE DERMATOLOGIE ET DE VENEREOLOGIE 119(4):281-283 BENSAID P; MACHET L; VAILLANT L; MACHET MC; SCOTTO B; LORETTE G ADULT LANGERHANS-CELL HISTIOCYTOSIS - REGRESSION OF PAROTID-GLAND INVOLVEMENT AFTER THALIDOMIDE TREATMENT | 13 | 18 |
156 | 3 | 6 | 471 1995 JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY 33(5):837-838 BERGER TG; HOFFMAN C; THIEBERG MD PRURIGO NODULARIS AND PHOTOSENSITIVITY IN AIDS - TREATMENT WITH THALIDOMIDE | 14 | 23 |
157 | 1 | 6 | 323 1992 INTERNATIONAL JOURNAL OF DERMATOLOGY 31(8):599-600 BERNAL JE; DURAN MM; LONDONO F; UMANA A CELLULAR IMMUNE EFFECTS OF THALIDOMIDE IN ACTINIC PRURIGO | 8 | 13 |
158 | 7 | 12 | 1748 2003 JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH 22(4):129-133 Bernardeschi P; Dentico P; Rossi S; Fiorentini G; Giustarini G; Turano E Low-dose thalidomide plus monthly high-dose oral dexamethasone (Thali-Dexa): Results, prognostic factors and side effects in eight patients previously treated with multiple myeloma | 0 | 0 |
159 | 0 | 0 | 290 1990 MEDICINA CLINICA 94(16):638-639 BERNARDO P; ARRIZABALAGA J; IRIBARREN JA; GARDE C EFFECTIVENESS OF THALIDOMIDE IN NONSPECIFIC ESOPHAGEAL ULCERS IN PATIENTS WITH HUMAN IMMUNODEFICIENCY SYNDROME | 3 | 4 |
160 | 1 | 236 | 596 1997 COLUMBIA LAW REVIEW 97(7):2153-2176 Bernstein A Formed by thalidomide: Mass torts as a false cure for toxic exposure | 1 | 6 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
161 | 6 | 16 | 1074 2001 ANNALS OF ONCOLOGY 12(7):987-990 Bertolini F; Mingrone W; Alietti A; Ferrucci PF; Cocorocchio E; Peccatori F; Cineri S; Mancuso P; Corsini C; Burlini A; Zucca E; Martinelli G Thalidomide in multiple myeloma, myelodysplastic syndromes and histiocytosis. Analysis of clinical results and of surrogate angiogenesis markers | 16 | 27 |
162 | 1 | 1 | 1076 2001 ANNALS OF ONCOLOGY 12(9):1333-1333 Bertolini F; Mingrone W; Alietti A; Ferrucci PF; Cocorocchio E; Peccatori F; Cinieri S; Mancuso P; Corsini C; Burlini A; Zucca E; Martinelli G Thalidomide in multiple myeloma, myelodysplastic syndromes and histiocytosis. Analysis of clinical results and of surrogate angiogenesis markers. (vol 12, pg 987, 2001) | 0 | 1 |
163 | 5 | 7 | 329 1992 LANCET 339(8792):549-550 BESSIS D; GUILLOT B; MONPOINT S; DANDURAND M; GUILHOU JJ THALIDOMIDE FOR SYSTEMIC LUPUS-ERYTHEMATOSUS | 27 | 31 |
164 | 27 | 34 | 1297 2002 ANNALS OF PHARMACOTHERAPY 36(3):521-525 Bessmertny O; Pham T Thalidomide use in pediatric patients | 1 | 2 |
165 | 2 | 5 | 798 1999 DERMATOLOGY 199(2):195-195 Bez C; Lodi G; Sardella A; Della Volpe A; Carrassi A Oral lichenoid lesions after thalidomide treatment | 5 | 5 |
166 | 10 | 38 | 1145 2001 BONE MARROW TRANSPLANTATION 28(12):1145-1150 Biagi JJ; Mileshkin L; Grigg AP; Westerman DW; Prince HM Efficacy of thalidomide therapy for extramedullary relapse of myeloma following allogeneic transplantation | 3 | 5 |
167 | 3 | 8 | 1156 2001 BRITISH JOURNAL OF HAEMATOLOGY 115(2):484-485 Biagi JJ; Prince HM Thalidomide is effective for extramedullary relapse of multiple myeloma postallogeneic bone marrow transplantation | 1 | 1 |
168 | 0 | 0 | 1120 2001 BLOOD 98(11):307B-307B Bibas M; Andriani A; Ferrari A; Montanaro M; Niscola G; Recine U; Chierichini A Thalidomide treatment for relapsed/refractory multiple myeloma: A retrospective multicenter study. | 0 | 0 |
169 | 14 | 22 | 402 1994 DERMATOLOGY 189(2):179-181 BIELSA I; TEIXIDO J; RIBERA M; FERRANDIZ C ERYTHRODERMA DUE TO THALIDOMIDE - REPORT OF 2 CASES | 13 | 17 |
170 | 0 | 0 | 1646 2003 BLOOD 102(11):554A-554A Biemond BJ; Havik SR; Meijers JCM; Levi MM; Van Oers MHJ Strong thrombogenic activity of the combined administration of thalidomide and doxorubicin in experimental thrombosis in the rabbit. | 0 | 0 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
171 | 0 | 1 | 51 1982 PRAXIS DER KINDERPSYCHOLOGIE UND KINDERPSYCHIATRIE 31(6):250-250 BIERMANN G THE ADOLESCENCE OF THALIDOMIDE DAMAGED CHILDREN - GERMAN - JOCHMUS,I, SCHMIDT,GM, LOHMAR,L, LOHMAR,W | 0 | 0 |
172 | 0 | 0 | 734 1998 NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY 358(1):R479-R479 Bignone IM; Papale RM; Seoane M; Bazerque PM Thalidomide - New trends for therapeutical use | 0 | 0 |
173 | 10 | 24 | 405 1994 FOLIA BIOLOGICA 40(4):161-171 BILA V; KREN V EVIDENCE FOR TERATOGENICITY OF THALIDOMIDE USING CONGENIC AND RECOMBINANT INBRED RAT STRAINS | 0 | 10 |
174 | 3 | 3 | 645 1997 NEW ENGLAND JOURNAL OF MEDICINE 337(15):1086-1087 Birnkrant D Thalidomide for aphthous ulcers in HIV infection | 1 | 2 |
175 | 0 | 0 | 1447 2002 EXPERIMENTAL HEMATOLOGY 30(6):60-60 Biscardi M; Gavazzi S; Balestri F; Grossi A Angiogenic growth factors (VEGF, TGF-b1, bFGF) and thalidomide effect in myelofibrosis with myeloid metaplasia | 0 | 0 |
176 | 6 | 18 | 1272 2001 SEMINARS IN ONCOLOGY 28(6):588-592 Blade J; Esteve J; Rosinol L; Perales M; Montoto S; Tuset M; Montserrat E Thalidomide in refractory and relapsing multiple myeloma | 11 | 13 |
177 | 5 | 12 | 1151 2001 BRITISH JOURNAL OF HAEMATOLOGY 113(2):422-424 Blade J; Perales M; Rosinol L; Tuset M; Montoto S; Esteve O; Cobo F; Villela L; Rafel M; Nomdedeu B; Montserrat E Thalidomide in multiple myeloma: lack of response of soft-tissue plasmacytomas | 18 | 19 |
178 | 9 | 21 | 1703 2003 CLINICAL LYMPHOMA 3(4):247-248 Blade J; Rosinol L Thalidomide: A step forward in the treatment of malignant monoclonal gammopathies | 0 | 0 |
179 | 0 | 0 | 52 1982 TERATOLOGY 25(2):A28-A29 BLAKE DA; GORDON GB; SPIELBERG SP THE ROLE OF METABOLIC-ACTIVATION IN THALIDOMIDE TERATOGENESIS | 0 | 0 |
180 | 7 | 18 | 1450 2002 FARMACO 57(7):551-554 Blaschke G; Meyring M; Muhlenbrock C; Chankvetadze B Recent results of biotransformation of drugs: investigation of the in vitro biotransformation of thalidomide using a dual cyclodextrin system in capillary electrophoresis | 0 | 2 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
181 | 2 | 3 | 375 1993 PRESSE MEDICALE 22(26):1233-1233 BODOKH I; LACOUR JP; RAINERO C; CASTANET J; MICHIELS JF; ORTONNE JP EFFECTIVENESS OF THALIDOMIDE AGAINST ESOPHAGEAL ULCERATION IN HIV-INFECTION | 3 | 3 |
182 | 13 | 15 | 1467 2002 HAUTARZT 53(11):744-748 Bohmeyer J; Achenbach A; Westenberger M; Stadler R Thalidomide therapy of cutaneous lupus erythematosus | 1 | 1 |
183 | 3 | 29 | 643 1997 NEUROSCIENCE LETTERS 234(2-3):123-126 Boireau A; Bordier F; Dubedat P; Peny C; Imperato A Thalidomide reduces MPTP-induced decrease in striatal dopamine levels in mice | 0 | 9 |
184 | 0 | 0 | 1772 2003 LANCET ONCOLOGY 4(2):70-70 Bonn D Thalidomide: no benefit in myelofibrosis with myeloid metaplasia | 0 | 0 |
185 | 7 | 9 | 521 1996 DERMATOLOGY 193(4):321-323 Bonnetblanc JM; Royer C; Bedane C Thalidomide and recurrent aphthous stomatitis: A follow-up study | 5 | 10 |
186 | 0 | 0 | 1180 2001 DIABETES 50:A473-A473 Bosco A; Lerario AC; Santos RF; Ferreira A; Ursich MJ; Silva ME; Rocha DM; Wajchenberg BL Study of Thalidomide and Rosiglitazone effects on the prevention of diabetic retinopathy of Streptozotocin diabetic rats | 0 | 0 |
187 | 6 | 42 | 1712 2003 DIABETOLOGIA 46(12):1669-1675 Bosco AA; Lerario AC; Santos RF; Wajchenberg BL Effect of thalidomide and rosiglitazone on the prevention of diabetic retinopathy in streptozotocin-induced diabetic rats | 1 | 1 |
188 | 1 | 1 | 1893 2004 DIABETOLOGIA 47(5):963-963 Bosco AA; Lerario AC; Santos RF; Wajchenberg BL Effect of thalidomide and rosiglitazone on the prevention of diabetic retinopathy in streptozotocin-induced diabetic rats (vol 46, pg 1669, 2003) | 0 | 0 |
189 | 0 | 0 | 1738 2003 JOURNAL OF BONE AND MINERAL RESEARCH 18:S310-S310 Bose N; Bergemann H; Westendorf JJ; Rajkumar SV; Masellis AM Expression of alternatively spliced Runx2 in multiple myeloma patients and a shift in expression in response to thalidomide treatment. | 0 | 0 |
190 | 0 | 0 | 192 1986 MEDICINA-BUENOS AIRES 46(5):528-528 BOTTASSO OA; MORINI JC; REGGIARDO Z ANTIBODIES AGAINST BCG GLYCOLIPIDS IN LEPROMATOUS PATIENTS TREATED WITH THALIDOMIDE OR LEPROUS KNOTTED ERYTHEMA | 0 | 0 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
191 | 3 | 34 | 1439 2002 DRUG NEWS & PERSPECTIVES 15(9):604-611 Botting J The history of thalidomide | 0 | 1 |
192 | 9 | 14 | 432 1995 ANNALS OF CLINICAL BIOCHEMISTRY 32:79-83 BOUGHTON BJ; SHEEHAN TMT; WOOD J; OBRIEN D; BUTLER M; SIMPSON A; HALE KA HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHIC ASSAY OF PLASMA THALIDOMIDE - STABILIZATION OF SPECIMENS AND DETERMINATION OF A TENTATIVE THERAPEUTIC RANGE FOR CHRONIC GRAFT-VERSUS-HOST DISEASE | 17 | 17 |
193 | 20 | 32 | 1555 2002 THERAPIE 57(6):524-529 Boulin M; Blanchet F; Isambert N; Solary E; Solier S; Collin B; Pernot C; Durnet-Archeray MJ Role of thalidomide with or without dexamethasone for refractory multiple myeloma | 0 | 0 |
194 | 0 | 0 | 240 1988 LEPROSY REVIEW 59(2):184-185 BOURDILLON C THALIDOMIDE IN ERYTHEMA-NODOSUM LEPROSUM (ENL) | 0 | 0 |
195 | 44 | 67 | 1184 2001 DRUGS 61(6):777-787 Bousvaros A; Mueller B Thalidomide in gastrointestinal disorders | 4 | 8 |
196 | 8 | 10 | 318 1992 ARCHIVES OF INTERNAL MEDICINE 152(5):1089-1090 BOUZA E; MUNOZ P; DIAZ MD; VICENTE T THALIDOMIDE IN PATIENTS WITH ACQUIRED-IMMUNODEFICIENCY-SYNDROME | 3 | 6 |
197 | 0 | 0 | 617 1997 JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES AND HUMAN RETROVIROLOGY 14(4):76-76 Bower M; Howard M; Gracie F; Phillips R; Fife K A phase II study of thalidomide for Kaposi's sarcoma: Activity and correlation with KSHV DNA load | 1 | 2 |
198 | 1 | 2 | 72 1983 BRITISH MEDICAL JOURNAL 287(6395):799-800 BOWERS PW; POWELL RJ EFFECT OF THALIDOMIDE ON OROGENITAL ULCERATION | 19 | 25 |
199 | 0 | 0 | 75 1983 BRITISH MEDICAL JOURNAL 287(6404):1550-1550 BOWERS PW; POWELL RJ EFFECT OF THALIDOMIDE ON OROGENITAL ULCERATION - REPLY | 1 | 1 |
200 | 7 | 10 | 1510 2002 JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY 47(6):967-968 Boyd AS; King LE; Boyd AS Thalidomide-induced remission of lichen planopilaris | 0 | 0 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
201 | 0 | 0 | 1016 2000 JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY 35(2):172A-173A Bozkurt B; Chee A; Lee-Jackson D; Deswal A; Zeldis JB; Mann DL Results of an open label dose response study of thalidomide in patients with advanced heart failure and elevated levels of TNF | 0 | 2 |
202 | 0 | 0 | 126 1984 TERATOLOGY 29(2):A19-A20 BRAUN AG; COLLINS M; HARDING F; WEINREB S FACTORS INFLUENCING THE ACTIVATION OF THALIDOMIDE TO A PRODUCT INHIBITING ATTACHMENT OF TUMOR-CELLS TO LECTIN COATED SURFACES | 0 | 1 |
203 | 0 | 20 | 10 1981 BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS 98(4):1029-1034 BRAUN AG; DAILEY JP THALIDOMIDE METABOLITE INHIBITS TUMOR-CELL ATTACHMENT TO CONCANAVALIN A COATED SURFACES | 6 | 16 |
204 | 2 | 15 | 198 1986 TOXICOLOGY AND APPLIED PHARMACOLOGY 82(1):175-179 BRAUN AG; HARDING FA; WEINREB SL TERATOGEN METABOLISM - THALIDOMIDE ACTIVATION IS MEDIATED BY CYTOCHROME-P-450 | 27 | 34 |
205 | 0 | 0 | 98 1983 TERATOLOGY 27(2):A33-A33 BRAUN AG; WEINREB SL METABOLITES OF THALIDOMIDE ANALOGS INHIBIT ATTACHMENT OF CELLS TO CONCANAVALIN A COATED SURFACES | 0 | 2 |
206 | 4 | 24 | 109 1984 BIOCHEMICAL PHARMACOLOGY 33(9):1471-1477 BRAUN AG; WEINREB SL TERATOGEN METABOLISM - ACTIVATION OF THALIDOMIDE AND THALIDOMIDE ANALOGS TO PRODUCTS THAT INHIBIT THE ATTACHMENT OF CELLS TO CONCANAVALIN A COATED PLASTIC SURFACES | 15 | 24 |
207 | 3 | 12 | 171 1985 TERATOGENESIS CARCINOGENESIS AND MUTAGENESIS 5(3):149-158 BRAUN AG; WEINREB SL TERATOGEN METABOLISM - SPONTANEOUS DECAY PRODUCTS OF THALIDOMIDE AND THALIDOMIDE ANALOGS ARE NOT BIOACTIVATED BY LIVER-MICROSOMES | 11 | 15 |
208 | 0 | 0 | 1396 2002 BRITISH JOURNAL OF CANCER 86:S42-S42 Braybrooke JP; Madhusudan S; Blann A; Wilner S; Flanagan E; Jenkins A; Echeta C; Perren T; Ganesan TS Randomised phase two study of carboplatin versus carboplatin and thalidomide in patients with ovarian cancer, with evaluation of potential surrogate markers of angiogenesis. | 0 | 0 |
209 | 1 | 4 | 1084 2001 ARTHRITIS AND RHEUMATISM 44(10):2457-2458 Breban M; Dougados M The efficacy of thalidomide in severe refractory seronegative spondylarthropathy: Reply | 2 | 5 |
210 | 3 | 8 | 754 1999 ARTHRITIS AND RHEUMATISM 42(3):580-581 Breban M; Gombert B; Amor B; Dougados M Efficacy of thalidomide in the treatment of refractory ankylosing spondylitis | 16 | 53 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
211 | 0 | 0 | 1621 2003 BLOOD 102(11):381B-381B Breitkreutz I; Cremer FW; Benner A; Moehler T; Fruehauf S; Herrmann D; Ho AD; Goldschmidt H Peripheral blood stem cell collection after CAD plus G-CSF in multiple myeloma: No influence of previous thalidomide administration. | 0 | 0 |
212 | 0 | 0 | 1362 2002 BLOOD 100(11):390B-390B Breitkreutz I; Cremer FW; Benner A; Raab MS; Moehler T; Egerer G; Christensen O; Herrmann D; Ho AD; Goldschmidt H Peripheral blood stem cell collection (PBSC) after CAD plus G-CSF in multiple myeloma: No influence of previous thalidomide (Thai) administration. | 0 | 0 |
213 | 7 | 25 | 1908 2004 HAEMATOLOGICA 89(5):552-556 Brenne AT; Romstad LH; Gimsing P; Juliusson G; Turesson I; Romundstad P; Borset M; Sundan A; Waage A Low serum level of soluble tumor necrosis factor receptor p55 predicts response to thalidomide in advanced multiple myeloma | 0 | 0 |
214 | 0 | 0 | 712 1998 JOURNAL OF INVESTIGATIVE DERMATOLOGY 110(4):693-693 Brenneman S; Burns R; Vink A; Gaines E; Haake A; Gaspari A Thalidomide inhibits UVB-induced mouse epidermal cell apoptosis by a TNF-alpha dependent pathway. | 0 | 0 |
215 | 3 | 219 | 248 1988 TERATOLOGY 38(3):241-251 BRENT RL; HOLMES LB CLINICAL AND BASIC SCIENCE LESSONS FROM THE THALIDOMIDE TRAGEDY - WHAT HAVE WE LEARNED ABOUT THE CAUSES OF LIMB DEFECTS | 7 | 37 |
216 | 7 | 10 | 1967 2004 NEUROLOGY 62(12):2288-2290 Briani C; Zara G; Rondinone R; Della Libera S; Ermani M; Ruggero S; Ghirardello A; Zampieri S; Doria A Thalidomide neurotoxicity - Prospective study in patients with lupus erythematosus | 1 | 1 |
217 | 8 | 16 | 1260 2001 PEDIATRIC DERMATOLOGY 18(2):143-145 Brik R; Shamali H; Bergman R Successful thalidomide treatment of severe infantile Behcet disease | 1 | 1 |
218 | 0 | 0 | 1335 2002 BLOOD 100(11):178A-178A Brinker B; Waller EK; Langston AA; Redei I; Smith KJ; Bucur SZ; Winton E; Lyles R; Heffner LT; Lonial S Therapy with thalidomide enhances overall survival after autologous PBSC transplant for multiple myeloma. | 0 | 0 |
219 | 0 | 16 | 272 1990 DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT 115(25):977-979 BROCHELER J; HALFMANN R ANTERIOR SACRAL MENINGOCELE ASSOCIATED WITH THALIDOMIDE EMBRYOPATHY | 0 | 0 |
220 | 7 | 11 | 1815 2003 PRESSE MEDICALE 32(40):1894-1898 Brocvielle H; Muret P; Plenat E; Kantelip JP; Humbert P Management of a patient receiving thalidomide | 0 | 0 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
221 | 1 | 2 | 160 1985 JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY 13(3):509-509 BRODTHAGEN H SIGNIFICANT RESPONSE OF ORAL APHTHOSIS TO THALIDOMIDE TREATMENT | 1 | 1 |
222 | 0 | 0 | 638 1997 NATURE BIOTECHNOLOGY 15(11):1238-1239 Brower V Thalidomide checks might have saved Redux | 0 | 1 |
223 | 0 | 0 | 639 1997 NATURE BIOTECHNOLOGY 15(12):1238-1239 Brower V Thalidomide checks might have saved Redux | 0 | 0 |
224 | 0 | 2 | 649 1997 SCIENTIST 11(3):1-& Brown KS New uses for thalidomide yielding valuable lessons | 1 | 4 |
225 | 1 | 1 | 650 1997 SCIENTIST 11(3):8-8 Brown KS Researchers explore thalidomide's therapeutic potential | 0 | 0 |
226 | 2 | 7 | 288 1990 MEDICAL JOURNAL OF AUSTRALIA 152(3):148-149 BROWN MA; FARRELL C; NEWTON P; CHILD RP THALIDOMIDE, PREGNANCY AND RENAL-FAILURE | 0 | 0 |
227 | 0 | 0 | 440 1995 BLOOD 86(10):1577-1577 Browne PV; Wagner J; Weisdorf DJ; DeFor T; Miller WJ; Davies SM; Filipovich A; McGlave PB; Ramsay NKC; Enright H Response to thalidomide therapy in patients with refractory chronic graft-versus-host disease. | 0 | 0 |
228 | 8 | 19 | 944 2000 BONE MARROW TRANSPLANTATION 26(8):865-869 Browne PV; Weisdorf DJ; DeFor T; Miller WJ; Davies SM; Filipovich A; McGlave PB; Ramsay NKC; Wagner J; Enright H Response to thalidomide therapy in refractory chronic graft-versus-host disease | 11 | 17 |
229 | 3 | 24 | 662 1998 ANTICANCER RESEARCH 18(6A):4409-4413 Browne WL; Wilson WR; Baguley BC; Ching LM Suppression of serum tumour necrosis factor-alpha by thalidomide does not lead to reversal of tumour vascular collapse and anti-tumour activity of 5,6-dimethylxanthenone-4-acetic acid | 5 | 13 |
230 | 6 | 12 | 750 1999 ANNALS OF ONCOLOGY 10(7):857-859 Bruera E; Neumann CM; Pituskin E; Calder K; Ball G; Hanson J Thalidomide in patients with cachexia due to terminal cancer: Preliminary report | 15 | 31 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
231 | 0 | 27 | 269 1990 ARZNEIMITTEL-FORSCHUNG/DRUG RESEARCH 40-1(1):32-36 BUCH HP; OMLOR G; KNABE J STEREOSELECTIVE DIFFERENCES OF THE CNS-DEPRESSANT ACTIVITY IN A HOMOLOGOUS SERIES OF 3-ALKYL-THALIDOMIDE ANALOGS | 0 | 5 |
232 | 0 | 1 | 1688 2003 BRITISH MEDICAL JOURNAL 327(7418):767-767 Burgermeister J Head of German medicines body likens HRT to thalidomide | 0 | 0 |
233 | 0 | 13 | 14 1981 EUROPEAN JOURNAL OF PEDIATRICS 136(3):229-230 BURGIO GR THE THALIDOMIDE DISASTER BRIEFLY REVISITED | 3 | 4 |
234 | 0 | 0 | 1533 2002 NEUROBIOLOGY OF AGING 23(1):S93-S93 Burke W; Bohac D; Cotter R; Zheng JL; Potter J; Gendelman H A 26 week double blind, placebo-controlled study of the efficacy of thalidomide in the treatment of Alzheimer's disease | 0 | 0 |
235 | 6 | 23 | 476 1995 MICROBIAL PATHOGENESIS 19(4):245-255 BURROUGHS MH; TSENOVABERKOVA L; SOKOL K; OSSIG J; TUOMANEN E; KAPLAN G EFFECT OF THALIDOMIDE ON THE INFLAMMATORY RESPONSE IN CEREBROSPINAL-FLUID IN EXPERIMENTAL BACTERIAL-MENINGITIS | 10 | 19 |
236 | 3 | 4 | 356 1993 BRITISH MEDICAL JOURNAL 307(6909):939-940 BURROWS NP DIAGNOSIS AND MANAGEMENT OF SYSTEMIC LUPUS-ERYTHEMATOSUS - THALIDOMIDE MODIFIES DISEASE | 1 | 1 |
237 | 2 | 34 | 300 1991 BRITISH JOURNAL OF DERMATOLOGY 125(1):62-67 BURROWS NP; WALPORT MJ; HAMMOND AH; DAVEY N; JONES RR LUPUS-ERYTHEMATOSUS PROFUNDUS WITH PARTIAL C4-DEFICIENCY RESPONDING TO THALIDOMIDE | 12 | 23 |
238 | 2 | 13 | 408 1994 JOURNAL OF CHEMICAL CRYSTALLOGRAPHY 24(1):95-99 CAIRA MR; BOTHA SA; FLANAGAN DR POLYMORPHISM OF N-(2,6-DIOXO-3-PIPERIDYL)PHTHALIMIDE (THALIDOMIDE) - STRUCTURAL CHARACTERIZATION OF A 2ND MONOCLINIC RACEMIC MODIFICATION | 0 | 2 |
239 | 62 | 96 | 877 2000 AMERICAN JOURNAL OF MEDICINE 108(6):487-495 Calabrese L; Fleischer AB Thalidomide: Current and potential clinical applications | 60 | 103 |
240 | 13 | 16 | 789 1999 CLEVELAND CLINIC JOURNAL OF MEDICINE 66(3):136-+ Calabrese LH Thalidomide's tightly controlled "comeback" | 3 | 3 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
241 | 1 | 2 | 1044 2000 PALLIATIVE MEDICINE 14(1):77-78 Calder K; Bruera E Thalidomide for night sweats in patients with advanced cancer | 6 | 7 |
242 | 48 | 74 | 607 1997 INTERNATIONAL JOURNAL OF DERMATOLOGY 36(12):881-887 Calderon P; Anzilotti M; Phelps R Thalidomide in dermatology. New indications for an old drug | 22 | 27 |
243 | 8 | 10 | 1205 2001 HAEMATOLOGICA 86(10):1108-1109 Camba L; Peccatori J; Pescarollo A; Tresoldi M; Corradini P; Bregni M Thalidomide and thrombosis in patients with multiple myeloma | 11 | 12 |
244 | 0 | 0 | 202 1987 ANNALES DE DERMATOLOGIE ET DE VENEREOLOGIE 114(9):1176-1176 CAMBAZARD F; LAFFAY A; VEDRINNE JM; THIVOLET J NEUROLOGICAL COMPLICATIONS OF THALIDOMIDE - STUDY OF 55 DERMATOLOGY PATIENTS (WITH THE EXCEPTION OF HANSENS-DISEASE PATIENTS) | 0 | 0 |
245 | 4 | 4 | 888 2000 ARCHIVES OF DERMATOLOGY 136(12):1442-1443 Camisa C; Popovsky JL Effective treatment of oral erosive lichen planus with thalidomide | 6 | 11 |
246 | 0 | 0 | 910 2000 BLOOD 96(11):266B-266B Canepa L; Ballerini F; Varaldo R; Grasso R; Clavio M; Miglino M; Pierri I; Gobbi M Myelofibrosis: Report of five cases treated with thalidomide. | 0 | 1 |
247 | 2 | 12 | 1155 2001 BRITISH JOURNAL OF HAEMATOLOGY 115(2):313-315 Canepa L; Ballerini F; Varaldo R; Quintino S; Reni L; Clavio M; Miglino M; Pierri I; Gobbi M Thalidomide in agnogenic and secondary myelofibrosis | 12 | 17 |
248 | 4 | 5 | 1486 2002 JOURNAL OF CLINICAL ONCOLOGY 20(8):2212-2212 Cany L; Fitoussi O; Boiron JM; Marit G Tumor lysis syndrome at the beginning of thalidomide therapy for multiple myeloma | 4 | 4 |
249 | 20 | 42 | 786 1999 BRITISH JOURNAL OF CANCER 80(5-6):716-723 Cao Z; Joseph WR; Browne WL; Mountjoy KG; Palmer BD; Baguley BC; Ching LM Thalidomide increases both intra-tumoural tumour necrosis factor-alpha production and anti-tumour activity in response to 5,6-dimethylxanthenone-4-acetic acid | 11 | 26 |
250 | 19 | 25 | 1807 2003 ORGANIC LETTERS 5(16):2865-2867 Capitosti SM; Hansen TP; Brown ML Facile synthesis of an azido-labeled thalidomide analogue | 0 | 2 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
251 | 11 | 43 | 1853 2004 BIOORGANIC & MEDICINAL CHEMISTRY 12(2):327-336 Capitosti SM; Hansen TP; Brown ML Thalidomide analogues demonstrate dual inhibition of both angiogenesis and prostate cancer | 0 | 2 |
252 | 10 | 44 | 1846 2004 ARCHIVES OF DERMATOLOGY 140(3):277-280 Caradona S; Jacobe H Thalidomide as a potential treatment for scleromyxedema | 0 | 0 |
253 | 0 | 0 | 1355 2002 BLOOD 100(11):385B-385B Caravita T; Arciprete F; Siniscalchi A; Santinelli S; Iani C; Amadori S Thalidomide induced neuropathy in patients treated for multiple myeloma. | 0 | 0 |
254 | 0 | 0 | 1625 2003 BLOOD 102(11):382B-383B Caravita T; Siniscalchi A; Niscola P; Santinelli S; Buccisano F; Montanaro M; De Fabritiis P; Amadori S Low dose thalidomide in combination with dexamethasone and cyclophosphamide for management of relapsed/refractory multiple myeloma. | 0 | 0 |
255 | 8 | 15 | 1963 2004 MICROCHEMICAL JOURNAL 77(1):1-7 Cardoso CE; Martins ROR; Aucelio RQ Evaluation of a spectrofluorimetric method for the selective determination of thalidomide in pharmaceutical tablets, urine and blood serum | 0 | 0 |
256 | 0 | 0 | 398 1994 CHEMISTRY IN BRITAIN 30(4):280-280 CAREY J THALIDOMIDE DEBATE - REPLY | 0 | 0 |
257 | 14 | 44 | 469 1995 JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY 32(5):866-869 CARLESIMO M; GIUSTINI S; ROSSI A; BONACCORSI P; CALVIERI S TREATMENT OF CUTANEOUS AND PULMONARY SARCOIDOSIS WITH THALIDOMIDE | 48 | 84 |
258 | 5 | 6 | 332 1992 LANCET 339(8805):1362-1362 CARMICHAEL AJ; KNIGHT A THALIDOMIDE - A RESTRICTED ROLE | 3 | 5 |
259 | 0 | 0 | 1326 2002 BLOOD 100(11):15B-15B Carneiro JDA; Garanito M; Halsman M; Matsumoto L; Odone V; del Giglio A Thalidomide as salvage therapy for acquired severe aplastice anemia (SAA) in children - Case report | 0 | 0 |
260 | 8 | 17 | 562 1996 TERATOLOGY 54(6):273-277 Castilla EE; AshtonProlla P; BarredaMejia E; Brunoni D; Cavalcanti DP; CorreaNeto J; Delgadillo JL; Dutra MG; Felix T; Giraldo A; Juarez N; LopezCamelo JS; Nazer J; Orioli IM; Paz JE; Pessoto MA; PinaNeto JM; Quadrelli R; Rittler M; Rueda S; Saltos M; Sanchez O; Schuler L Thalidomide, a current teratogen in South America | 14 | 17 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
261 | 0 | 0 | 1645 2003 BLOOD 102(11):490B-490B Castro J; Davila J; Perez S; Flores L; Lopez A; Roman A; Pacheco E; Fernandex A; Fradera J; Garcia R; Merle S; Velez-Garcia E High dose chemotherapy (HDC) with autologous transplant (AT) followed by thalidomide (T) as maintenance in patients (P) with multiple myeloma (MM). | 0 | 0 |
262 | 0 | 0 | 932 2000 BLOOD 96(11):367B-367B Castro J; Talavera A; Tejeda C; Cortes L; Fradera J; Velez-Garcia E Preliminary experience of the use of thalidomide maintenance therapy after autologous transplant in patients with multiple myeloma (MM). | 0 | 0 |
263 | 0 | 0 | 167 1985 NEW SOCIETY 74(1196):369-371 CAUDREY A THALIDOMIDE GENERATION | 0 | 0 |
264 | 7 | 10 | 1968 2004 NEUROLOGY 62(12):2291-2293 Cavaletti G; Beronio A; Reni L; Ghiglione E; Schenone A; Briani C; Zara G; Cocito D; Isoardo G; Ciaramitaro P; Plasmati R; Pastorelli F; Frigo M; Piatti M; Carpo M Thalidomide sensory neurotoxicity - A clinical and neurophysiologic study | 1 | 1 |
265 | 19 | 50 | 1676 2003 BRITISH JOURNAL OF HAEMATOLOGY 120(1):18-26 Cavenagh JD; Oakervee H; UK Myeloma Forum; BSCH Haematology Oncology Task For Thalidomide in multiple myeloma: Current status and future prospects | 15 | 18 |
266 | 8 | 8 | 1325 2002 BLOOD 100(6):2272-2273 Cavo M; Zamagni E; Cellini C; Tosi P; Cangini D; Cini M; Valdre L; Palareti G; Masini L; Tura S; Baccarani M Deep-vein thrombosis in patients with multiple myeloma receiving first-line thalidomide-dexamethasone therapy | 11 | 15 |
267 | 19 | 37 | 1909 2004 HAEMATOLOGICA 89(7):826-831 Cavo M; Zamagni E; Tosi P; Cellini C; Cangini D; Tacchetti P; Testoni N; Tonelli M; De Vivo A; Palareti G; Tura S; Baccarani M First-line therapy with thalidomide and dexamethasone in preparation for autologous stem cell transplantation for multiple myeloma | 0 | 0 |
268 | 0 | 0 | 1635 2003 BLOOD 102(11):448A-448A Cavo M; Zamagni E; Tosi P; Cellini C; de Vivo A; Cangini D; Tonelli M; Testoni N; Grafone T; Tacchetti P; Soverini S; Terragna C; Tura S; Baccarani M Primary therapy with thalidomide and dexamethasone in preparation to autologous transplantation for multiple myeloma. | 0 | 0 |
269 | 9 | 60 | 878 2000 AMERICAN JOURNAL OF NEURORADIOLOGY 21(5):881-890 Cha S; Knopp EA; Johnson G; Litt A; Glass J; Gruber ML; Lu S; Zagzag D Dynamic contrast-enhanced T2*-weighted MR imaging of recurrent malignant gliomas treated with thalidomide and carboplatin | 3 | 24 |
270 | 0 | 0 | 554 1996 NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY 22(5):456-456 Chakrabarty A; Bridges LR Cerebral malformation in a patient with thalidomide related phocomelia | 0 | 0 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
271 | 0 | 6 | 255 1989 BRITISH MEDICAL JOURNAL 298(6665):6-6 CHAMBERLAIN G THE OBSTETRIC PROBLEMS OF THE THALIDOMIDE CHILDREN | 0 | 0 |
272 | 0 | 0 | 1647 2003 BLOOD 102(11):675A-675A Chanan-Khan AA; Fallon A; Miller K; Bernstein ZP; Hernandez F; Alam A; McCarthy P; Mohr A; Czuczman MS Thalidomide (T) and fludarabine (F) as front-line therapy for patients (pts) with previously untreated chronic lymphocytic leukemia (CLL): Results of a phase I trial. | 0 | 0 |
273 | 0 | 0 | 1632 2003 BLOOD 102(11):389B-389B Chanan-Khan AA; Miller K; Srinivasan S; David S; McCarthy P; Alam A; Bernstein ZP; Czuczman MS Velcade (Vel), Doxil (R) (Dox) and low-dose thalidomide (Thal) as salvage therapy for patients (pts) with relapsed/refractory multiple myeloma (MM). | 0 | 0 |
274 | 0 | 0 | 1616 2003 BLOOD 102(11):353B-353B Chanan-Khan AA; Stein L; David S; Takeshita K; Platt J; Miller K; Fallon A; Czuczman MS; Hawthorn L Thalidomide (T) induced in vivo changes in gene expression profile (GEP) of malignant chronic lymphocytic leukemia (CLL) cells. | 0 | 0 |
275 | 3 | 16 | 1513 2002 JOURNAL OF THE CHINESE CHEMICAL SOCIETY 49(3):383-385 Chang MY; Chang CH; Chen ST; Chang NC A synthesis of thalidomide | 0 | 9 |
276 | 4 | 19 | 1827 2003 SYNTHETIC COMMUNICATIONS 33(8):1375-1382 Chang MY; Chen ST; Chang NC A synthesis of racemic thalidomide | 0 | 4 |
277 | 14 | 23 | 1917 2004 INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS 60(2):353-357 Chang SM; Lamborn KR; Malec M; Larson D; Wara W; Sneed P; Rabbitt J; Page M; Nicholas MK; Prados MD Phase II study of temozolomide and thalidomide with radiation therapy for newly diagnosed glioblastoma multiforme | 0 | 0 |
278 | 6 | 30 | 170 1985 REVUE NEUROLOGIQUE 141(11):719-728 CHAPON F; LECHEVALIER B; DASILVA DC; RIVRAIN Y; DUPUY B; DESCHAMPS P THALIDOMIDE INDUCED NEUROPATHY | 5 | 8 |
279 | 0 | 0 | 467 1995 JOURNAL OF INVESTIGATIVE DERMATOLOGY 105(3):479-479 CHARUE D; CHAUVIN E; DUGUET C; REVUZ J; BAGOT M THALIDOMIDE DECREASES THE PRODUCTION OF GM-CSF AND TNF-ALPHA IN MIXED EPIDERMAL-CELL LYMPHOCYTE-REACTION | 2 | 2 |
280 | 14 | 24 | 524 1996 EUROPEAN JOURNAL OF DERMATOLOGY 6(5):373-376 Charue D; Chauvin E; Duguet C; Revuz J; Bagot M Thalidomide decreases the production of GM-CSF and TNF-alpha in the mixed epidermal cell-lymphocyte reaction | 1 | 2 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
281 | 0 | 0 | 553 1996 NEUROLOGY 46(2):27003-27003 Chaudhry V; Cornblath D; Corse A; Freimer M; SimmonsOBrien E; Vogelsang G Thalidomide-induced neuropathy: Clinical and electrophysiological features | 0 | 0 |
282 | 13 | 29 | 1534 2002 NEUROLOGY 59(12):1872-1875 Chaudhry V; Cornblath DR; Corse A; Freimer M; Simmons-O'Brien E; Vogelsang G Thalidomide-induced neuropathy | 7 | 9 |
283 | 24 | 32 | 1149 2001 BRITISH JOURNAL OF DERMATOLOGY 144(2):310-315 Chave TA; Finlay AY; Knight AG; All-Wales Dermatology Audit Comm Thalidomide usage in Wales: the need to follow guidelines | 1 | 1 |
284 | 2 | 10 | 1974 2004 TRANSPLANTATION PROCEEDINGS 36(4):1018-1020 Chaves DNB; Petroianu A; Alberti LR; Pereira WA Effects of thalidomide, cyclosporine, and diclofenac on skin allograft survival in rabbits | 0 | 0 |
285 | 0 | 0 | 769 1999 BLOOD 94(10):308B-308B Chen CI; Adesanya A; Sutton DM; Brandwein J; Stewart AK Low-dose thalidomide in patients with advanced, refractory multiple myeloma. | 0 | 1 |
286 | 10 | 41 | 1918 2004 JOURNAL OF BIOMEDICAL SCIENCE 11(5):591-598 Chen CS; Perng WC; Chen CW; Huang KL; Wu CP; Yen MH Thalidomide reduces lipopolysaccharide/zymosan-induced acute lung injury in rats | 0 | 0 |
287 | 2 | 5 | 581 1997 BONE MARROW TRANSPLANTATION 19(1):95-96 Chen F; Tsang K; Liang R Thalidomide-responsive chronic pulmonary GVHD | 0 | 0 |
288 | 0 | 0 | 1470 2002 INTERNATIONAL JOURNAL OF CANCER :336-337 Chen LT; Chao Y; Yao TJ; Huang JD; Chang JY; Chin YH; Chuang TR; Reed E; Whang-Peng J; Liu TW Phase I and pharmacokinetic studies of oral thalidomide in advanced hepatocellular carcinoma | 0 | 0 |
289 | 9 | 24 | 257 1989 DRUG METABOLISM AND DISPOSITION 17(4):402-405 CHEN TL; VOGELSANG GB; PETTY BG; BRUNDRETT RB; NOE DA; SANTOS GW; COLVIN OM PLASMA PHARMACOKINETICS AND URINARY-EXCRETION OF THALIDOMIDE AFTER ORAL DOSING IN HEALTHY MALE-VOLUNTEERS | 77 | 81 |
290 | 0 | 0 | 773 1999 BLOOD 94(10):315A-315A Cheng D; Kini AR; Rodriguez J; Burt RK; Peterson LC; Traynor AE Microvascular density and cytotoxic T cell activation correlate with response to thalidomide therapy in myeloma patients. | 0 | 8 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
291 | 3 | 13 | 497 1996 ANNALES DE DERMATOLOGIE ET DE VENEREOLOGIE 123(6-7):375-377 Cherouati K; Claudy A; Souteyrand P; Cambazard F; Vaillant L; Moulin G; Crickx B; Morel P; Lamorelle A; Revuz J Thalidomide treatment of chronic erythema multiforme recurrent and continuous variants. A retrospective study of 26 patients. | 6 | 7 |
292 | 7 | 17 | 1586 2003 APMIS 111:113-116 Chew M; Zhou J; Daugherty A; Eriksson T; Ellermann-Eriksen S; Hansen PR; Falk E Thalidomide inhibits early atherogenesis in apoE-deficient mice | 0 | 0 |
293 | 4 | 9 | 1737 2003 JCR-JOURNAL OF CLINICAL RHEUMATOLOGY 9(2):96-98 Ching DWT; McClintock A; Beswick F Successful treatment with low-dose thalidomide in a patient with both Behcet's disease and complex regional pain syndrome type I - Case report | 0 | 0 |
294 | 0 | 0 | 1699 2003 CLINICAL CANCER RESEARCH 9(14):5429-5429 Ching LM; Baguley BC; Kestell P; Palmer BD; Lu J Correspondence re: J. Lu et al., Thalidomide metabolites in mice and patients with multiple myeloma. Clin. Cancer Res., 9 : 1680-1688, 2003. - Reply | 0 | 0 |
295 | 7 | 24 | 684 1998 BRITISH JOURNAL OF CANCER 78(3):336-343 Ching LM; Browne WL; Tchernegovski R; Gregory T; Baguley BC; Palmer BD Interaction of thalidomide, phthalimide analogues of thalidomide and pentoxifylline with the anti-tumour agent 5,6-dimethylxanthenone-4-acetic acid: concomitant reduction of serum tumour necrosis factor-alpha and enhancement of anti-tumour activity | 16 | 27 |
296 | 4 | 25 | 442 1995 BRITISH JOURNAL OF CANCER 72(2):339-343 CHING LM; XU ZF; GUMMER BH; PALMER BD; JOSEPH WR; BAGULEY BC EFFECT OF THALIDOMIDE ON TUMOR-NECROSIS-FACTOR PRODUCTION AND ANTITUMOR-ACTIVITY INDUCED BY 5,6-DIMETHYLXANTHENONE-4-ACETIC ACID | 28 | 44 |
297 | 0 | 0 | 389 1994 BRITISH MEDICAL JOURNAL 308(6931):739-739 CHRISTIE B THALIDOMIDE VICTIMS WIN REVIEW OF COMPENSATION | 2 | 2 |
298 | 22 | 33 | 1888 2004 CLINICAL CANCER RESEARCH 10(17):5949-5956 Chung F; Lu J; Palmer BD; Kestell P; Browett P; Baguley BC; Tingle M; Ching LM Thalidomide pharmacokinetics and metabolite formation in mice, rabbits, and multiple myeloma patients | 0 | 0 |
299 | 13 | 28 | 1879 2004 CANCER CHEMOTHERAPY AND PHARMACOLOGY 53(5):377-383 Chung F; Wang LCS; Kestell P; Baguley BC; Ching LM Modulation of thalidomide pharmacokinetics by cyclophosphamide or 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in mice: the role of tumour necrosis factor | 2 | 2 |
300 | 0 | 0 | 1861 2004 BONE MARROW TRANSPLANTATION 33:S160-S161 Ciepluch H; Knopinska-Posluszny W; Czyz J; Hellmann A Employment of autologous transplantation of progenitor cells following effective treatment with thalidomide of patients with multiple myeloma resistant to conventional chemotherapy | 0 | 0 |